HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Julio Gomez-Soriano Selected Research

Org 48762-0

9/2015Early treatment with UR13870, a novel inhibitor of p38α mitogenous activated protein kinase, prevents hyperreflexia and anxiety behaviors, in the spared nerve injury model of neuropathic pain.
10/2014Oral administration of the p38α MAPK inhibitor, UR13870, inhibits affective pain behavior after spinal cord injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Julio Gomez-Soriano Research Topics

Disease

2Neuralgia (Stump Neuralgia)
09/2015 - 10/2014
2Pain (Aches)
09/2015 - 10/2014
1Abnormal Reflex (Hyperreflexia)
09/2015
1Hypersensitivity (Allergy)
09/2015
1Spinal Cord Injuries (Spinal Cord Injury)
10/2014

Drug/Important Bio-Agent (IBA)

2Org 48762-0IBA
09/2015 - 10/2014
2Protein Kinases (Protein Kinase)IBA
09/2015 - 10/2014
1Pregabalin (Lyrica)FDA Link
09/2015
1N-Methylaspartate (NMDA)IBA
10/2014
1Glutamate Receptors (Glutamate Receptor)IBA
10/2014
1Glutamic Acid (Glutamate)FDA Link
10/2014

Therapy/Procedure

1Oral Administration
10/2014